SCHEMBL10751699

SCHEMBL10751699

CC(N)C(C)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.56
ESR2 Q92731 6/20 0.56
PDCD1 Q15116 1/20 0.56
CD274 Q9NZQ7 1/20 0.56
TAAR1 Q96RJ0 5/20 0.46
SLC6A2 P23975 2/20 0.46
TDP1 Q9NUW8 6/20 0.44
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
ALOX15 P16050 3/20 0.44
CYP1A2 P05177 1/20 0.44
PGR P06401 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
AR P10275 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
CYP2C9 P11712 1/20 0.44
DRD1 P21728 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14156380 1.00 ESR1 (0.56) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL14156465 1.00 ESR1 (0.56) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL11949347 0.84 ESR1 (0.68) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL30753092 0.84 ESR1 (0.68) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL4247422 0.84 ESR1 (0.68) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL29351491 0.84 ESR1 (0.68) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL5329242 0.83 ESR1 (0.54) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL20371199 0.79 ESR1 (0.62) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL2631307 0.79 ESR1 (0.62) ESR1ESR2PDCD1CD274TAAR1
SCHEMBL2032476 0.79 ESR1 (0.62) ESR1ESR2PDCD1CD274TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus SEATTLE GENETICS, INC. (US) 2018-06-19 US disclosed
US-20130123465-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2013-05-16 US disclosed
US-8343928-B2 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus SEATTLE GENETICS, INC. (US) 2013-01-01 US disclosed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 WO disclosed
US-4659737-A Substituted aminomethyl benzopyrans having anti-hypertensive activities BAYER AKTIENGESELLSCHAFT (DE) 1987-04-21 US disclosed
US-4647579-A Circulation active novel substituted 4-hydroxy-benzopyrans BAYER AKTIENGESELLSCHAFT (DE) 1987-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123465-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS MMAB, PTMS, DNPEP ESR1 4092/4885ESR2 3871/4885PDCD1 992/4885
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus PTMS, MMAB, DNPEP ESR1 4145/4885ESR2 3945/4885PDCD1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.